Lancet Oncol: Pym mono-anti-combination therapy first-line treatment of HER2-positive metastatic esophageal gastric cancer

Adding qutoberitosic resistance to first-line chemotherapy can improve the overall survival rate of HER2-positive metastatic gastric cancer patientsRecently, researchers evaluated the efficacy of pymmonotares, quto-bead monoantigens, and combined first-line chemotherapy in her2-positive metastatic esophageal gastric (gastric, esophagus, or gastroesophageal junctions) in cancerthis study was phase II trial, involving patients 18 years of age or older with HER2-positive metastatic esophageal gastric cancer, first 200 mg pym monoantigen and 8 mg/kg of coctain monoantigenSubsequently, on the first day, the patient received 130 mg/m 2 osaliplatinum or 80 mg/m 2 of cisplatin treatment, twice daily oral cappetin850 mg/m 2, for a period of 2 weeks, after 1 week interval, on the first day of each 3 weeks, intravenously 200 mg of pymmono and 6 mg/kg of cantibody bead edbinThe main endpoint of the study was six months of progression-free survival37 patients participated in the study, with a median follow-up time of 13.0 months, reaching the main endpointTwenty-six (70 per cent) of the 37 patients had no progress at six monthsThe most common level of treatment-related adverse events is neuropathy (97%)The most common level 3 or 4 adverse events are lymphocyte reduction (7 cases of 19 per cent to stage 3, 2 cases of level 4), level 3 electrolyte reduction (6 cases of 16 per cent) and level 3 anemia (4 cases of 11 per cent)Two patients had severe adverse events (both of which resulted in a suspension of treatment due to stage 3 nephritis)Four patients stopped using pymmonotares due to adverse immune-related reactionsThere are no treatment-related deathspym mono-anti-and quto-bead-resistant combined chemotherapy can effectively prolong the progression of HER2-positive patients with metastatic esophageal gastric cancer